Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.

Trial Profile

Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2015

At a glance

  • Drugs Clofarabine (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Planned end date changed from Oct 2009 to Oct 2010 as reported by ClinicalTrials.gov.
    • 14 Nov 2007 Expected recruitment has been reduced to 21 from 40 participants.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top